PHATHOM PHARMACEUTICALS, INC.
PHAT · NASDAQ
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders.
Market Data
Price
$10.76
+0.39 (+3.76%)
Market Cap—
P/E Ratio—
EPS$—
52W High$—
52W Low$—
Beta—
Data from Finnhub · Updated Jun 15, 2026